Perrigo saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks typically have an RS Rating of at least 80 in the early stages of their moves. See if Perrigo can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear an appropriate buy point.
While EPS growth declined in the company's most recent performance report from 27% to 8%, sales rose -2%, up from -3% in the prior report.
Perrigo earns the No. 5 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
